Fundz

Elevation Oncology Appoints Julie Cherrington as Chief Executive Officer and Alan Sandler as Chief Medical Officer

PRIVATEMar 04, 2024

Position

Chief Executive Officer

Company

Elevation Oncology

Julie Cherrington
BostonBiotechnologyHealthcareHealth CareMedicalGeneticsTherapeutics

Description

Elevation Oncology announces the appointments of Julie Cherrington, Ph.D. as Chief Executive Officer and Alan Sandler, M.D. as Chief Medical Officer.

Other recent leadership changes in Healthcare and Medical

Executive moves at companies in the same sectors within 45 days, from Fundz verified event records.

Who to call at Elevation Oncology, and when

A new leader at Elevation Oncology brings new priorities and often new vendors. The first weeks are when they listen.

  • An alert the day Elevation Oncology raises, hires an executive or expands, scored against what you sell
  • The decision-makers there, with verified emails
  • Who you already know at Elevation Oncology, from your own LinkedIn network

Works inside ChatGPT and Claude. Ask who to call at Elevation Oncology. With Fundz connected, it knows.

Watch Fundz in
See plan options
Trusted byOracleSnowflakeCloudflareLinkedInGoogleSalesforce 4.8/5 on G2

Company Information

Company

Elevation Oncology

Location

888 SEVENTH AVE

Boston, Massachusetts, United States

About

Elevation Oncology is founded on the belief that every patient living with cancer deserves to know what is driving the growth of their disease and have access to therapeutics that can stop it. We aim to make genomic tests actionable by selectively developing drugs to inhibit the specific alterations that have been identified as drivers of tumor growth. Together with our peers, we work towards a future in which each tumor's unique genomic test result can be matched with a purpose-built precision medicine to enable an individualized treatment plan for each patient. Our most advanced candidate, seribantumab, is intended to inhibit tumor growth driven by NRG1 fusions and is currently being evaluated in the Phase 2 CRESTONE study for patients with solid tumors of any origin that have an NRG1 gene fusion. Details on CRESTONE are available at www.NRG1fusion.com. Our other product candidate, EO-3021, is a differentiated, clinical stage antibody drug conjugate that targets Claudin18.2 and is currently being developed for the treatment of genomically defined solid tumors. For more information, visit www.ElevationOncology.com.

AI made execution free. Knowing first is the whole game now.

Fundz sees it the moment Elevation Oncology changes its leadership, hires an exec or expands, usually minutes after it happens, and tells you who to reach.

Related People

Joseph
Likely contact at this company
••••••••@••••••••

See Joseph's verified email →

Create an account to reveal verified emails
Predictive Intelligence
Strategic

ML-powered predictions for Elevation Oncology's next move

Learn about Strategic plan

Elevation Oncology changed its leadership. Fundz had it the day it was filed, with the decision-maker at the company attached.

145 of these a day, filtered to the companies you pick, with the decision-maker attached.

5 screens from a live account. No signup.

Fundz is a real-time business intelligence platform powered by agentic AI that proactively delivers personalized daily signals, including funding rounds, executive changes, M&A activity, 13F institutional filings, SEC 8-K events, investor activity, and website modifications, based on each user's watchlist and ICP. A trusted data source at firms such as BlackRock, Oracle, Kleiner Perkins, LinkedIn, HubSpot, and Cloudflare, Fundz democratizes the institutional-grade intelligence that previously required a PitchBook or Bloomberg terminal. Features include Daily Briefing for AI-powered daily briefings, and unified cross-signal alerts across 281,000+ organizations. Developers and data teams can access these signals programmatically via the Fundz Funding Data API, with transparent published pricing.